Clene Inc. (CLNN)
CLNN Stock Price Chart
Explore Clene Inc. interactive price chart. Choose custom timeframes to analyze CLNN price movements and trends.
CLNN Company Profile
Discover essential business fundamentals and corporate details for Clene Inc. (CLNN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Oct 2018
Employees
75.00
Website
https://clene.comCEO
Robert Etherington MBA
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
CLNN Financial Timeline
Browse a chronological timeline of Clene Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.60.
Earnings released on 14 Aug 2025
EPS came in at -$0.78 falling short of the estimated -$0.49 by -59.18%, while revenue for the quarter reached $27.00K , missing expectations by -51.03%.
Earnings released on 7 May 2025
EPS came in at -$0.50 surpassing the estimated -$1.10 by +54.55%, while revenue for the quarter reached $81.00K , beating expectations by +26.84%.
Earnings released on 24 Mar 2025
EPS came in at -$1.67 falling short of the estimated -$1.21 by -38.02%, while revenue for the quarter reached $91.00K , missing expectations by -30.00%.
Earnings released on 13 Nov 2024
EPS came in at -$1.22 surpassing the estimated -$1.34 by +8.96%, while revenue for the quarter reached $87.00K , missing expectations by -44.23%.
Earnings released on 7 Aug 2024
EPS came in at -$1.06 surpassing the estimated -$1.60 by +33.75%, while revenue for the quarter reached $91.00K , missing expectations by -9.00%.
Stock split effective on 11 Jul 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 May 2024
EPS came in at -$1.80 matching the estimated -$1.80, while revenue for the quarter reached $73.00K , missing expectations by -39.17%.
Earnings released on 13 Mar 2024
EPS came in at -$1.20 surpassing the estimated -$1.40 by +14.29%, while revenue for the quarter reached $170.00K , beating expectations by +21.43%.
Earnings released on 7 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$2.00 by +80.00%, while revenue for the quarter reached $108.00K , missing expectations by -10.00%.
Earnings released on 14 Aug 2023
EPS came in at -$2.40 surpassing the estimated -$2.60 by +7.69%, while revenue for the quarter reached $269.00K , beating expectations by +124.17%.
Earnings released on 12 May 2023
EPS came in at -$3.00 surpassing the estimated -$3.20 by +6.25%, while revenue for the quarter reached $107.00K , missing expectations by -17.69%.
Earnings released on 13 Mar 2023
EPS came in at -$3.20 falling short of the estimated -$3.00 by -6.67%, while revenue for the quarter reached $234.00K , beating expectations by +112.73%.
Earnings released on 7 Nov 2022
EPS came in at -$2.80 surpassing the estimated -$4.60 by +39.13%, while revenue for the quarter reached $174.00K , beating expectations by +100.77%.
Earnings released on 15 Aug 2022
EPS came in at -$4.40 falling short of the estimated -$4.20 by -4.76%, while revenue for the quarter reached $35.00K , missing expectations by -58.00%.
Earnings released on 9 May 2022
EPS came in at -$4.20 falling short of the estimated -$3.60 by -16.67%, while revenue for the quarter reached $30.00K , missing expectations by -63.86%.
Earnings released on 11 Mar 2022
EPS came in at -$3.80 falling short of the estimated -$3.60 by -5.56%, while revenue for the quarter reached $199.00K , beating expectations by +71.18%.
Earnings released on 9 Nov 2021
EPS came in at -$0.60 surpassing the estimated -$4.40 by +86.36%, while revenue for the quarter reached $110.00K , beating expectations by +83.33%.
Earnings released on 10 Aug 2021
EPS came in at -$4.20 falling short of the estimated -$2.00 by -110.00%, while revenue for the quarter reached $201.00K , beating expectations by +19.72%.
Earnings released on 11 May 2021
EPS came in at -$3.80 falling short of the estimated -$1.80 by -111.11%, while revenue for the quarter reached $213.00K .
Earnings released on 29 Mar 2021
EPS came in at $0.01 surpassing the estimated -$0.09 by +111.11%, while revenue for the quarter reached $29.00K .
Earnings released on 18 Dec 2020
EPS came in at -$1.68 , while revenue for the quarter reached $9.00K .
Earnings released on 30 Sept 2020
EPS came in at -$2.97 , while revenue for the quarter reached $98.00K .
CLNN Stock Performance
Access detailed CLNN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.